Apeloa Pharmaceutical Co.,Ltd
000739
Hisse Senetlerindeki Sıralama
#4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Hisse Fiyatı
$3.13
Piyasa Değeri
$3.62B
Değişim (1 gün)
-1.42%
Değişim (1 yıl)
46.59%
Ülke
CN
Ticaret Apeloa Pharmaceutical Co.,Ltd (000739)
Kategori
Healthcare
Apeloa Pharmaceutical Co.,Ltd (000739) için gelir
Jun 2026 itibarıyla gelir TTM: $1.33B
Apeloa Pharmaceutical Co.,Ltd şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $1.33B'dir. 2024 yılında şirketin geliri $1.65B önceki yıla göre artış 2023 yılındaki $1.62B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Apeloa Pharmaceutical Co.,Ltd için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $1.33B | -4.81% |
| 2025 | $1.39B | -15.31% |
| 2024 | $1.65B | 1.61% |
| 2023 | $1.62B | 6.03% |
| 2022 | $1.53B | 8.65% |
| 2021 | $1.41B | 16.65% |
| 2020 | $1.21B | 16.48% |
| 2019 | $1.04B | 11.72% |
| 2018 | $926.93M | 8.63% |
| 2017 | $853.30M | 24.14% |
| 2016 | $687.35M | 2.89% |
| 2015 | $668.02M | -2.25% |
| 2014 | $683.37M | 7.52% |
| 2013 | $635.58M | 13.89% |
| 2012 | $558.08M | 25.04% |
| 2011 | $446.31M | 93.68% |
| 2010 | $230.44M | 15.01% |
| 2009 | $200.35M | 11.32% |
| 2008 | $179.98M | 26.18% |
| 2007 | $142.64M | -5.97% |
| 2006 | $151.70M | 18.26% |
| 2005 | $128.27M | 27.82% |
| 2004 | $100.36M | 7.83% |
| 2003 | $93.07M | 16.84% |
| 2002 | $79.66M | 364.75% |
| 2001 | $17.14M | -20.73% |
| 2000 | $21.62M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 397.95% |
IN
|
